Author

Paresh Sewpaul

Observed name: P. Sewpaul

Institution: Roche (United Kingdom)

Observed institutions: GlaxoSmithKline (United Kingdom), Roche (United Kingdom), Novo Nordisk (United Kingdom)

OpenAlex ID: A5001708077

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

2024 · Michel Delforge, Joshua Richter, et al. · Blood · 7

12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies

2015 · Savino Bruno, Paresh Sewpaul, et al. · Digestive and Liver Disease · 2

OA-11 Cevostamab Plus Pomalidomide (Pom) and Dexamethasone (Dex) Induces Durable Remissions in BCMA-Naïve Patients With Relapsed/Refractory Multiple Myeloma (RRMM): CAMMA 1 Arm B Extended Follow-Up Data

2026 · Andrew Spencer, Hira S. Mian, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

P34 | Cevostamab Plus Pomalidomide and Dexamethasone in Patients With Relapsed/refractory Multiple Myeloma: Biomarker Analyses From Camma 1 Arm B

2026 · R. Popat, S. Harrison, et al. · Haematologica · 1

Cevostamab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM): Phase I Dose-Expansion Results from the CAMMA 1 Study

2025 · Hira S. Mian, Caroline Hasselbalch Riley, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

The Evolution Between 2001 and 2010 In the Uk Costs of Resolving a Mild to Moderate Bleeding Episode with Pd-aPCC Versus rFVIIa In Haemophilia A Patients with inhibitors.

2010 · Paresh Sewpaul, Donna Ashley, et al. · Blood · 1

PA-069 CEVOLUTION: A Randomized Phase III Trial Comparing Cevostamab Plus Pomalidomide and Dexamethasone (Pom-Dex) Versus Standard of Care (SOC) in Relapsed/Refractory Multiple Myeloma (RRMM)

2026 · Rakesh Popat, Adam D. Cohen, et al. · Clinical Lymphoma Myeloma & Leukemia

P1159 Safety Assessment of 12 Week Interferon-based Regimen in Hcv G1 Cirrhotic Patients With Poor Clinical Characteristics

2014 · S. Bruno, P. Sewpaul, et al. · Journal of Hepatology

Works count: 8

Citation count: 13

H-index: 2

I10-index: